CGON: CG Oncology Corp Analyst Target Range

CG Oncology, Inc. (CGON) is diversifying its development portfolio by combining monotherapy and combination regimens, which mitigates regulatory risks. This chart on GURU.Markets visualizes this process, where the metric stands at 91.72. However, sanctions and severed ties are hindering global trials. Meanwhile, demand for bladder cancer treatment creates a steady cash flow, eliminating the risk of technological obsolescence.

CGON CG Oncology Inc Price Target Chart (02/21/2024 - 11/14/2026)

Analytical breakdowns for CG Oncology Corp (CGON)

- market price and analyst price targets:

Stock Quotes cgoncology.com|CGON - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization CG Oncology Corp|CGON - Total Company Value

- book capitalization data:

Net Asset Value per Share CG Oncology|CGON - Company Book Value|Capitalization to Book Value Ratio cgoncology.com|CGON - Company Total Assets

- issuer credit burden and liquidity indicators:

- earnings and multiples data:

CGON - Company Net Income|Expected Net Income CG Oncology, Inc.|CGON - Price to Earnings Ratio|Future Price to Earnings Multiple CG Oncology Inc|CGON - PEG Multiple|Enterprise Value to EBITDA Ratio CG Oncology Corp|CGON - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) CG Oncology|CGON - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months cgoncology.com|CGON - Earnings growth in current year|Expected net earnings per share growth next year CG Oncology, Inc.

- total revenue and sales volume data:

CGON - Revenue and Sales Volume|Company Future Sales Volume cgoncology.com|CGON - P/S Multiple|Projected Price to Revenue CG Oncology Corp

Fundamental company analysis:cgoncology.com (CGON)

This indicator determines the fundamental value of an asset via an averaged Wall Street expert benchmark, filtering out market noise. The consensus estimated value on GURU.Markets helps investors accurately locate the bottom and identify business overvaluation. The metric is based on the aggregation of verified financial data, excluding subjective forecasts. For CG Oncology, Inc. (CGON), this reflects the high liquidity of the commercial sector. Robust demand for bladder cancer therapy minimizes obsolescence risks.

Competing companies